Stroke prevention treatment of patients with atrial fibrillation: old and new
- PMID: 21086074
- DOI: 10.1007/s11910-010-0161-z
Stroke prevention treatment of patients with atrial fibrillation: old and new
Abstract
Atrial fibrillation is the most common cause of cardioembolic ischemic stroke and has a rising prevalence worldwide. Stroke prevention in this condition is poised to take a substantial leap forward with the evolution of new anticoagulant medications, with superior properties compared to vitamin K antagonists. New, safer and more effective chronic therapy is on the horizon. However, many issues surrounding the management of stroke prevention after an acute stroke and during the course of chronic anticoagulant therapy remain to be resolved.
Similar articles
-
Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.Curr Opin Cardiol. 2012 Jul;27(4):331-9. doi: 10.1097/HCO.0b013e3283540857. Curr Opin Cardiol. 2012. PMID: 22573171 Review.
-
Stroke Prevention in Nonvalvular Atrial Fibrillation: A Stakeholder Perspective.J Am Coll Cardiol. 2018 Jun 19;71(24):2790-2801. doi: 10.1016/j.jacc.2018.04.013. J Am Coll Cardiol. 2018. PMID: 29903352 Review.
-
Prevention of cardioembolic stroke in patients with atrial fibrillation.Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1405-15. doi: 10.1586/erc.10.103. Expert Rev Cardiovasc Ther. 2010. PMID: 20936927 Review.
-
Clinical Stroke prevention in atrial fibrillation.J R Coll Physicians Edinb. 2017 Mar;47(1):13-23. doi: 10.4997/JRCPE.2017.105. J R Coll Physicians Edinb. 2017. PMID: 28569277 Review.
-
Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.Cardiol Rev. 2016 Sep-Oct;24(5):218-23. doi: 10.1097/CRD.0000000000000088. Cardiol Rev. 2016. PMID: 26274538 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical